Vaxxinity, Inc.
Vaxxinity, Inc. (VAXX): 8 pipeline candidates · ~8 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.6 months
D/E 2.30
Lead: Phase 2
8 candidates
N/A
N/A
A transparent, data-derived signal for Vaxxinity, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$13K
Cash
$5.0M
Quarterly Burn
$11.8M
Runway
7.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$43
| Holder | Shares | Value |
|---|---|---|
| nbc securities, inc. | 1,592 | $43 |
Frequently asked questions
How many drug candidates are in Vaxxinity, Inc.'s pipeline?
Vaxxinity, Inc. (VAXX) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Vaxxinity, Inc.'s lead drug candidate?
Vaxxinity, Inc.'s most advanced tracked candidate is anti-pcsk9 (Preclinical) for Hypercholesterolemia.
What is Vaxxinity, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Vaxxinity, Inc. has approximately 7.6 months of cash runway.
What is Vaxxinity, Inc.'s market capitalization?
Vaxxinity, Inc.'s market capitalization is approximately $13K.
Who is the CEO of Vaxxinity, Inc.?
Ms. Mei Mei Hu J.D. is the chief executive officer of Vaxxinity, Inc. (VAXX).
Get the full picture on Vaxxinity, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.